4-[(4-Acetyl-3-hydroxy-2-propylphenyl)methoxy]benzaldehyde | 172931-84-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-[(4-Acetyl-3-hydroxy-2-propylphenyl)methoxy]benzaldehyde
• CAS: 172931-84-9
• 化学式: C₁₉H₂₀O₄
• 分子量: 312.365
• InChiKey: SCYQHCWDYIWVRW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  23
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-[(4-Acetyl-3-hydroxy-2-propylphenyl)methoxy]benzaldehyde 在 sodium hydride 、 对甲苯磺酸 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 生成
  参考文献：
  名称：

  Synthesis and structure-activity relationships of benzophenones as inhibitors of cathepsin D

  摘要：

  Non peptide inhibitors of cathepsin D, an aspartyl protease that has been implicated in many disease states including Alzheimer's disease, were prepared and evaluated. The most potent inhibitor of cathepsin D in this series was found to be (Z)-5-[[4-(4-benzoyl-3-hydroxy-2-propylphenoxy)methylphenyl]methylene]-2-thioxo-4-thiazolidinone (3f, IC50 = 210 nM). Copyright (C) 1996 Elsevier Science Ltd

  DOI：

  10.1016/0960-894x(96)00393-9
• 作为产物：
  描述：

  对羟基苯甲醛 、 1-<4-(chloromethyl)-2-hydroxy-3-propylphenyl>ethanone 在 base 作用下， 生成 4-[(4-Acetyl-3-hydroxy-2-propylphenyl)methoxy]benzaldehyde
  参考文献：
  名称：

  Synthesis and structure-activity relationships of benzophenones as inhibitors of cathepsin D

  摘要：

  Non peptide inhibitors of cathepsin D, an aspartyl protease that has been implicated in many disease states including Alzheimer's disease, were prepared and evaluated. The most potent inhibitor of cathepsin D in this series was found to be (Z)-5-[[4-(4-benzoyl-3-hydroxy-2-propylphenoxy)methylphenyl]methylene]-2-thioxo-4-thiazolidinone (3f, IC50 = 210 nM). Copyright (C) 1996 Elsevier Science Ltd

  DOI：

  10.1016/0960-894x(96)00393-9

文献信息

• A novel class of 5-HT2a receptor antagonists: Aryl aminoguanidines
  作者：Henry U. Bryant、David L. Nelson、Donald Button、Harlan W. Cole、Melvyn B. Baez、Virginia L. Lucaites、David B. Wainscott、Cecilia Whitesitt、Jon Reel、Richard Simon、Gary A. Koppel

  DOI：10.1016/0024-3205(96)00449-3

  日期：1996.9

  is prevented by 5-HT2 antagonists such as ketanserin or mianserin. Here we report the effects of a new class of aminoguanidine 5-HT2 antagonists, with relative selectivity for 5-HT2A receptors which are potent inhibitors of 5-HT-induced paw edema in the rat. Radioligand binding studies with 125I DOI on human 5-HT2A and 5-HT2C receptors and with 3H-5-HT on human 5-HT2B receptors demonstrated that, LY314228

  血清素（5-HT）的局部递送通过增加的液体外渗在软组织中产生快速的水肿反应，而5-HT2拮抗剂（如酮色林或米安色林）阻止了这种现象。在这里，我们报告了新型的氨基胍5-HT2拮抗剂的作用，对5-HT2A受体具有相对选择性，5-HT2A受体是大鼠中5-HT诱导的爪水肿的有效抑制剂。用125 I DOI对人5-HT2A和5-HT2C受体以及对3H-5-HT对人5-HT2B受体的放射性配体结合研究表明，LY314228和LY320954对5-HT2A受体表现出一定的选择性。与其他5-HT2受体亚型的结合相比，LY314228对5-HT2A的亲和力比5-HT2B的亲和力高18.6倍，对5-HT2C的亲和力则高2.6倍。LY320954对5-HT2A位点显示出相似的偏好。两种化合物均能抑制5-HT诱导的大鼠足肿胀，ED50为6.4和4.8 mg / kg（分别针对LY314228和LY320954）。这些研究为5-HT
• Benzylidene rhodanines
  申请人：Eli Lilly and Company

  公开号：US05747517A1

  公开（公告）日：1998-05-05

  This invention provides novel benzylidene rhodanines which are useful as agents in treating or preventing conditions associated with .beta.-amyloid peptide. This invention further provides methods of treating or preventing Alzheimer's Disease which comprises administering to a mammal in need thereof an effective amount of one or more of the benzylidene rhodanines of the present invention.

  本发明提供了新型苄基亚硫酰罗丹明，其可用作治疗或预防与β-淀粉样肽相关的疾病的药物。本发明还提供了治疗或预防阿尔茨海默病的方法，该方法包括向需要的哺乳动物中施用本发明中的一种或多种苄基亚硫酰罗丹明的有效量。
• Treatment of alzheimer's disease employing inhibitors of cathepsin D
  申请人：Eli Lilly and Company

  公开号：US06251928B1

  公开（公告）日：2001-06-26

  This invention provides novel benzylidene rhodanines which are useful as agents in treating or preventing conditions associated with &bgr;-amyloid peptide. This invention further provides methods of treating or preventing Alzheimer's Disease which comprises administering to a mammal in need thereof an effective amount of one or more of the benzylidene rhodanines of the present invention.

  本发明提供了一种新型的苯甲醛基硫氰酸酯，可用作治疗或预防与β-淀粉样肽相关的疾病的药剂。本发明还提供了治疗或预防阿尔茨海默病的方法，包括向需要的哺乳动物中给予本发明中的一种或多种苯甲醛基硫氰酸酯的有效量。
• Treatment of Alzheimer's disease employing inhibitors of cathepsin D
  申请人：ELI LILLY AND COMPANY

  公开号：EP0677517A1

  公开（公告）日：1995-10-18

  This invention provides novel benzylidene rhodanines of the formula wherein nis 0, 1, 2, 3, or 4; qis 0, 1, 2, 3, or 4; Ais -O, -NH-, or -S(O)m-;    where m is 0, 1, or 2; R¹is hydrogen, C₁-C₆ alkyl, di(C₁-C₆ alkyl)amino-, amino, (C₁-C₆ alkyl)amino-, cyano(C₁-C₆ alkyl)-, or carboxy(C₁-C₆ alkylidenyl)-; Ris phenyl, oxazolyl, benzophenonyl, or naphthyl optionally substituted with one or more substituents, which are useful as agents in treating or preventing conditions associated with β-amyloid peptide. This invention further provides methods of treating or preventing Alzheimer's Disease which comprises administering to a mammal in need thereof an effective amount of one or more of the benzylidene rhodanines of the present invention. This invention also provides methods for reducing blood glucose concentrations which comprises administering to a mammal in need thereof an effective amount of one or more of the benzylidene rhodanines of the present invention.

  本发明提供了式如下的新型亚苄基罗丹宁 式中 n为0、1、2、3或4； q为0、1、2、3或4； A是-O、-NH-或-S(O)m-； 其中 m 为 0、1 或 2； R¹是氢、C₁-C₆烷基、二(C₁-C₆烷基)氨基、氨基、(C₁-C₆烷基)氨基、氰基(C₁-C₆烷基)-或羧基(C₁-C₆亚烷基)-； 里氏苯基、恶唑基、二苯甲酮基或任选被一个或多个取代基取代的萘基，可用作治疗或预防与 β 淀粉样肽相关的疾病的药物。本发明进一步提供了治疗或预防阿尔茨海默病的方法，其中包括向有需要的哺乳动物施用有效量的一种或多种本发明的亚苄基罗丹宁。本发明还提供了降低血糖浓度的方法，其中包括向有需要的哺乳动物施用有效量的一种或多种本发明的亚苄基罗丹宁。
• US5747517A
  申请人：——

  公开号：US5747517A

  公开（公告）日：1998-05-05